{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:18:05Z","timestamp":1773951485170,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>To date, over 60% of the world's population has received at least 1 dose of coronavirus disease 2019 (COVID-19) vaccination, with over 12 billion doses administered globally. Commonly reported adverse effects of COVID-19 vaccination include fever, headache, myalgia, and injection site reactions. The spectrum of documented cutaneous reactions after COVID-19 vaccination is broad; however, pityriasis rubra pilaris (PRP) or PRP-like eruption secondary to COVID-19 vaccine is exceedingly rare, with only 17 cases previously reported to date in the English literature. In this article, we describe an additional case of COVID-19 vaccination-associated PRP in a 50-year-old woman with a history of metastatic breast carcinoma, who developed a widespread cutaneous eruption characteristic of PRP, including palmoplantar keratoderma, 10 days after her third dose of Moderna COVID-19 vaccine. Punch biopsy specimen showed epidermal hyperplasia with overlying hyperkeratosis, alternating orthokeratosis and parakeratosis and focal follicular plugging, supporting the diagnosis of PRP. The patient improved within weeks of initiating oral acitretin and topical steroids, with resolution achieved after 3 months of continued therapy. To the best of our knowledge, this is the third reported case of Moderna COVID-19 vaccination-associated PRP and collectively the 18<jats:sup>th<\/jats:sup> after the administration of all COVID-19 vaccines currently available, including Pfizer\u2013BioNTech, and AstraZeneca.<\/jats:p>","DOI":"10.1097\/dad.0000000000002369","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T19:48:19Z","timestamp":1673380099000},"page":"185-188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Pityriasis Rubra Pilaris After Moderna COVID-19 Vaccination: A Case Report and Literature Review"],"prefix":"10.1097","volume":"45","author":[{"given":"Yi A.","family":"Liu","sequence":"first","affiliation":[{"name":"Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Dai","sequence":"additional","affiliation":[{"name":"Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[{"name":"Pathology, and"},{"name":"Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyu P.","family":"Aung","sequence":"additional","affiliation":[{"name":"Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[{"name":"Pathology, and"},{"name":"Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-1403","authenticated-orcid":false,"given":"Woo Cheal","family":"Cho","sequence":"additional","affiliation":[{"name":"Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdin.2022.01.011","article-title":"Cutaneous reactions to COVID-19 vaccines: a review","volume":"7","author":"Tan","year":"2022","journal-title":"JAAD Int."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ced.14970","article-title":"Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine","volume":"47","author":"Sechi","year":"2022","journal-title":"Clin Exp Dermatol."},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4103\/0378-6323.168326","article-title":"Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines","volume":"81","author":"Mohamed","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.annder.2011.01.049","article-title":"[Pityriasis rubra pilaris after vaccination]","volume":"138","author":"Naciri Bennani","year":"2011","journal-title":"Ann Dermatol Venereol."},{"key":"R10-20250616","first-page":"S226","article-title":"A case of pityriasis rubra pilaris induced by DTPolio Vaccination","volume":"124","author":"Musette","year":"1997","journal-title":"Ann Dermatol Venerol"},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1111\/jdv.18214","article-title":"Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection","volume":"36","author":"Gambichler","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1111\/jdv.17424","article-title":"Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features","volume":"35","author":"Kadylak","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1111\/jocd.14933","article-title":"Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: decoding a possible trigger","volume":"21","author":"Arora","year":"2022","journal-title":"J Cosmet Dermatol."},{"key":"R14-20250616","article-title":"COVID-19 induced pityriasis rubra pilaris: a superantigenic disease?","author":"Aromolo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"e7014577","DOI":"10.25100\/cm.v52i1.4577","article-title":"Pityriasis rubra pilaris post-infection due COVID-19: case report","volume":"52","author":"Aguilar-Gamboa","year":"2021","journal-title":"Colomb Med (Cali)."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000240018","article-title":"Pityriasis rubra pilaris with preceding cytomegalovirus infection","volume":"219","author":"Kawara","year":"2009","journal-title":"Dermatology"},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3760\/cma.j.issn.0366-6999.20133239","article-title":"Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: a new type PRP with non-HIV virus infection?","volume":"127","author":"Wang","year":"2014","journal-title":"Chin Med J (Engl)."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JRS-210048","article-title":"An old entity, a new trigger: post COVID-19 vaccine pityriasis rubra pilaris","volume":"32","author":"Sahni","year":"2021","journal-title":"Int J Risk Saf Med."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1111\/jdv.17542","article-title":"Pityriasis rubra pilaris after Vaxzevria(R) COVID-19 vaccine","volume":"35","author":"Llado","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1111\/jdv.18055","article-title":"Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: a report of two cases with successful treatment with oral isotretinoin","volume":"36","author":"Criado","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2022.04.020","article-title":"A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine","volume":"24","author":"Wada","year":"2022","journal-title":"JAAD Case Rep."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00105-022-04972-z","article-title":"[Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?]","volume":"73","author":"Bramhoff","year":"2022","journal-title":"Dermatologie (Heidelb)"},{"key":"R23-20250616","first-page":"e139","article-title":"Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination","author":"Liu","year":"2022","journal-title":"Skin Health Dis."},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"e15455","DOI":"10.1111\/dth.15455","article-title":"Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac)","volume":"35","author":"Fernandez","year":"2022","journal-title":"Dermatol Ther."},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2022.03.013","article-title":"Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine","volume":"23","author":"Ajebo","year":"2022","journal-title":"JAAD Case Rep."},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ced.14878","article-title":"Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine","volume":"47","author":"Hunjan","year":"2022","journal-title":"Clin Exp Dermatol."},{"key":"R27-20250616","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/dermato2030008","article-title":"First onset of pityriasis rubra pilaris following SARS-CoV-2 booster vaccination: case report and review of the literature","volume":"2","author":"Gambichler","year":"2022","journal-title":"Dermato"},{"key":"R28-20250616","first-page":"e15791","article-title":"Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine","author":"Hlaca","year":"2022","journal-title":"Dermatol Ther."},{"key":"R29-20250616","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clindermatol.2021.07.011","article-title":"The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin","volume":"39","author":"Magro","year":"2021","journal-title":"Clin Dermatol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:04:28Z","timestamp":1750097068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002369","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"2022-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}